checkAd
    Startseite > Aktien > Gritstone bio > Nachrichten
    Gritstone bio Aktie
    0,7369
     
    USD
    -1,17 %
    -0,0087 USD
    Letzter Kurs 02:00:00 Nasdaq
    0,7369
     
    USD
    10.200 STK
    Geldkurs 10.06.24
    0,7419
     
    USD
    1.200 STK
    Briefkurs 10.06.24
    ISIN: US39868T1051 · WKN: A2N4RX · SYM: GRTS · USA

    Neueste Nachrichten

    GRITSTONE INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Gritstone bio, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – GRTS
    10.06.24 · Business Wire (engl.) · Gritstone bio
    Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
    04.06.24 · globenewswire · Gritstone bio
    Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
    09.05.24 · globenewswire · Gritstone bio
    Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024
    02.05.24 · globenewswire · Gritstone bio
    Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024
    30.04.24 · globenewswire · Gritstone bio
    Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors
    29.04.24 · globenewswire · Gritstone bio
    Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
    15.04.24 · globenewswire · Gritstone bio
    Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
    08.04.24 · globenewswire · Gritstone bio
    Gritstone bio Presents Improvements to EDGE Platform at AACR 2024
    08.04.24 · globenewswire · Gritstone bio
    Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering
    02.04.24 · globenewswire · Gritstone bio
    Gritstone bio Announces Proposed Public Offering
    01.04.24 · globenewswire · Gritstone bio
    Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite St
    01.04.24 · globenewswire · Gritstone bio